Suppr超能文献

早产儿动脉导管未闭

Patent Ductus Arteriosus in Preterm Infants.

作者信息

Ambalavanan Namasivayam, Aucott Susan W, Salavitabar Arash, Levy Victor Y

机构信息

University of Alabama at Birmingham, Birmingham, Alabama.

Division of Neonatology, Greater Baltimore Medical Center, Baltimore, Maryland.

出版信息

Pediatrics. 2025 May 1;155(5). doi: 10.1542/peds.2025-071425.

Abstract

Despite extensive research in basic science and in clinical settings with thousands of infants over decades, uncertainty and controversy persist regarding the significance, assessment, and management of the patent ductus arteriosus (PDA) in preterm infants, resulting in substantial variability in clinical approach. This clinical report aims to succinctly review the available evidence to guide evaluation and treatment of preterm infants with prolonged ductal patency. Delayed closure of the PDA is common in preterm infants, particularly at more extreme immaturity. Echocardiography is essential for confirming the presence of a PDA and assessing hemodynamic significance. Medical closure of a PDA using ibuprofen or acetaminophen is an option for a hemodynamically significant PDA (hsPDA). Recent data from multiple clinical trials indicate the lack of benefits of prophylactic or early (<2 weeks of age) medical closure of PDA as compared with expectant management, and they are, therefore, not recommended. There are insufficient data to support firm recommendations on management of infants with an hsPDA beyond 2 weeks of age as relative benefits and risks of expectant management with close monitoring, attempted pharmacologic closure, or procedural (transcatheter/surgical) closure have not been adequately defined. Many clinicians attempt medical closure of an hsPDA beyond 2 weeks of age. If the hsPDA persists despite medical therapy (or if medical therapy is contraindicated), such infants may be considered for either transcatheter closure or surgical ligation. In recent years, surgical closure of the PDA has become less frequent, and transcatheter closure is more common in many centers. Although there are known adverse effects of an hsPDA, there is a lack of evidence to guide management, necessitating equipoise regarding treatment options and timing and a need for trials that can expand the available body of evidence, especially regarding long-term cardiopulmonary and neurodevelopmental outcomes.

摘要

尽管几十年来在基础科学和临床环境中对数千名婴儿进行了广泛研究,但关于早产儿动脉导管未闭(PDA)的意义、评估和管理仍存在不确定性和争议,导致临床处理方式存在很大差异。本临床报告旨在简要回顾现有证据,以指导对导管持续开放的早产儿进行评估和治疗。PDA延迟关闭在早产儿中很常见,尤其是在极不成熟的情况下。超声心动图对于确认PDA的存在和评估血流动力学意义至关重要。使用布洛芬或对乙酰氨基酚进行药物性关闭PDA是血流动力学显著的PDA(hsPDA)的一种选择。多项临床试验的最新数据表明,与期待治疗相比,预防性或早期(<2周龄)药物性关闭PDA没有益处,因此不推荐。对于2周龄以上患有hsPDA的婴儿的管理,由于期待治疗密切监测、尝试药物性关闭或程序性(经导管/手术)关闭的相对益处和风险尚未得到充分界定,因此没有足够的数据支持明确的管理建议。许多临床医生尝试对2周龄以上的hsPDA进行药物性关闭。如果尽管进行了药物治疗hsPDA仍持续存在(或如果药物治疗禁忌),可考虑对这类婴儿进行经导管关闭或手术结扎。近年来,PDA的手术关闭频率降低,经导管关闭在许多中心更为常见。尽管已知hsPDA有不良影响,但缺乏指导管理的证据,这就需要在治疗选择和时机方面保持平衡,并且需要开展试验以扩大现有证据,特别是关于长期心肺和神经发育结局的证据。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验